Some countries are worried about the uneven distribution of new crown oral drugs

By yqqlm yqqlm

Beijing, October 13 (Xinhua) according to Singapore’s Lianhe Zaobao, the new crown oral drug developed by American pharmaceutical company Merck has not been approved, and many countries have ordered it first. Experts therefore worry that the history of uneven distribution of vaccines similar to the new crown will repeat, and poor countries may be left behind again

according to an independent survey commissioned by the World Health Organization, there is no clear procurement structure for countries to supply new crown drugs or negotiate procurement agreements. Countries that are still struggling to vaccinate their people may fall behind again in the procurement of therapeutic drugs

Some countries are worried about the uneven distribution of new crown oral drugs

the survey report supported by who calls for “rapid preventive” measures to avoid the recurrence of the problems encountered by the “global access mechanism for new crown vaccine” (covax). The mechanism is responsible for coordinating the distribution of vaccines, but the vaccine supply is tight because rich countries are eager to protect their people. At this time, some rich countries have begun to inject additional vaccines for their nationals

Cohen, the North American executive director of the non-profit organization “drug research and development initiative for neglected diseases”, pointed out that the emergence of new antiviral drugs is good news, but it is necessary to strengthen testing to find the disease in the first few days of infection, because taking drugs at this time may be the most effective

however, the price of drugs and who will be able to obtain them, or who will not be able to obtain them if the supply is limited, are still key issues

in June this year, the United States agreed to purchase 1.7 million “molnupiravir” courses from Merck for about US $1.2 billion, or about US $700 per course. Australia, Malaysia, Singapore and New Zealand subsequently locked in the supply, and Thailand is also finalizing the final agreement

according to the estimation of airfinity, a scientific data analysis company, about 10 countries or regions have signed agreements or are negotiating with Merck

Merck has applied to the United States for emergency use authorization of “monabilavir”. The company expects to produce 10 million treatment courses by the end of this year and further expand its supply next year

Merck also disclosed that it has signed an agreement with Indian pharmaceutical manufacturers. Once oral drugs are approved for use, Indian pharmaceutical manufacturers can assist in providing drugs to more than 100 low – and middle-income countries